![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switch to dolutegravir in HIV patients responding to a first line antiretroviral treatment- 48 weeks results
|
|
|
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
Luba Tau*1, Tomer Ziv-Baran2, Ronit Cohen-Poradosu1, Ari Leshno1, Danny Alon1, David Shasha1, Steven Rappaport1, Asaf Wasserman1, Talya Finn1, Eugene Katchman1, David Hassin1, Israel Yust1, Boaz Avidor1,3 Dan Turner1
1Crusaid Kobler AIDS Center Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine , Tel-Aviv University, Tel-Aviv, Israel.
2School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Laboratory for Viruses and Molecular Biology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
![HCV1](../images/120216/120216-1/HCV1.gif)
![HCV2](../images/120216/120216-1/HCV2.gif)
![HCV3](../images/120216/120216-1/HCV3.gif)
![HCV4](../images/120216/120216-1/HCV4.gif)
![HCV5](../images/120216/120216-1/HCV5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|